News
Biogen touted an “unprecedented” drop in tau in a Phase 2 trial, backing the company’s decision to take diranersen to Phase 3 despite a missed primary endpoint and seemingly supporting the anti-tau approach.
FEATURED STORIES
As antibody-drug conjugates advance and move into earlier lines of treatment, drug developers have to build gentler therapies that don’t just extend survival but improve it.
FDA’s rare disease decisions are strongest when the patient community has a voice in advisory committee decisions.
The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurodegenerative disease.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Let’s talk about some common mistakes job candidates make during interviews, so you can steer clear of them for your next interview! Here’s how to nail a job interview.
Here’s a look at mRNA vaccines and their effectiveness and more COVID-19 news.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Fresh out of the gates with $500 million in financing, Neumora Therapeutics forged a partnership with Amgen to develop and commercialize assets for neurodegenerative diseases.
Pfizer’s exec team is hit with a double whammy as another c-suite leader announces his retirement.
Denali Therapeutics reported positive Phase I data and regulatory progress for two therapeutics for ALS at the virtual 2021 Annual Northeast ALS Meeting.
Litigator Block & Leviton is launching an investigation into Ginkgo Bioworks after short seller Scorpion Capital released a report alleging that Ginkgo is running a fraudulent operation.
The question is continually being raised: what offers superior protection, a vaccine against COVID-19 or natural immunity?
The patch is not only painless, it requires less vaccine to generate the same or greater effects.
Attorneys for Holmes have speculated that the lab failures at Theranos are the fault of Rosendorf and not Holmes herself.